Management of Hepatocellular Carcinoma Patients with Portal Vein Thrombosis Using Three-Dimensional Conformal Radiotherapy  

作　　者：Ahmed Abo Gabal Mohamed Lotayef Hoda Abd Elbaky Maha Hassan Heba Elzawahry Ekram Hamed 

机构地区：[1]Department of Radiation Oncology, National Cancer Institute, Cairo University, Cairo, Egypt [2]Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt [3]Department of Radio-Diagnosis, National Cancer Institute, Cairo University, Cairo, Egypt

出　　处：《Journal of Cancer Therapy》2017年第6期579-590,共12页癌症治疗（英文）

摘　　要：Objective: To determine the possible therapeutic gain of using three-dimensional conformal radiotherapy (3D-CRT) as a treatment option for portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma (HCC) and to evaluate the tolerance and toxicity of using such treatment. Materials and methods: Sixty two patients were enrolled in this prospective study between June 2013 and August 2015. The clinical target volume (CTV) was the PVTT and the prescribed dose was 50 Gy/25 fractions. The median follow-up time was 7.4 months. Results: The thrombus crude response rate was 40.4% and the only significant prognostic factor for response was the thrombus size. Responders had significant better survival compared to non-responders with a median survival of 12.5 and 8 months respectively (P Conclusions: The results of this study suggest that radiotherapy should be considered as a safe treatment option for HCC patients with PVTT. It is effective not only for PVTT local control but also for survival, although prospective randomized trials are needed to confirm these results.Objective: To determine the possible therapeutic gain of using three-dimensional conformal radiotherapy (3D-CRT) as a treatment option for portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma (HCC) and to evaluate the tolerance and toxicity of using such treatment. Materials and methods: Sixty two patients were enrolled in this prospective study between June 2013 and August 2015. The clinical target volume (CTV) was the PVTT and the prescribed dose was 50 Gy/25 fractions. The median follow-up time was 7.4 months. Results: The thrombus crude response rate was 40.4% and the only significant prognostic factor for response was the thrombus size. Responders had significant better survival compared to non-responders with a median survival of 12.5 and 8 months respectively (P Conclusions: The results of this study suggest that radiotherapy should be considered as a safe treatment option for HCC patients with PVTT. It is effective not only for PVTT local control but also for survival, although prospective randomized trials are needed to confirm these results.

关 键 词：HEPATOCELLULAR Carcinoma PORTAL VEIN THROMBOSIS 3D CONFORMAL Radiotherapy PORTAL VEIN Tumor THROMBUS 

分 类 号：R73[医药卫生—肿瘤]